检索结果-南通市图书馆

Pancreatic paraganglioma with draining vessels

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第31期21卷 9442-9447页

作者： Yoshitsugu Misumi Toshio Fujisawa Hirotsugu Hashimoto koichi kagawa Tamaki Noie Hideyuki Chiba Hajime Horiuchi Yasushi Harihara Nobuyuki Matsuhashi Department of Gastroenterology NTT Medical Center Tokyo Department of Pathology NTT Medical Center Tokyo Department of Surgery NTT Medical Center Tokyo Department of Gastroenterology Omori Red Cross Hospital

A pancreatic paraganglioma is a rare neoplasm that is difficult to distinguish from a pancreatic neuroendocrine tumour. Here we present a case of pancreatic paraganglioma that was surgically resected following preoperative diagnosis of a pancreatic neuroendocrine tumour. Careful evaluation of the endoscopic ultrasonography findings revealed abundant draining ves-sels,which could have led to a correct preoperative diagnosis of pancreatic paraganglioma.

关键词： Paraganglioma Neuroendocrine tumour Draining vesse

Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2014年第9期6卷 670-676页

作者： Masako Shomura Tatehiro kagawa koichi Shiraishi Shunji Hirose Yoshitaka Arase Tetsuya Mine Jun Koizumi Department of Nursing Tokai University School of Health SciencesIseharaKanagawa 2591193Japan Division of Gastroenterology Department of Internal MedicineTokai University School of MedicineIs-eharaKanagawa 2591193Japan Department of Radiology Tokai University School of MedicineIseharaKanagawa 2591193Japan

AIM:To study the relationship between adverse events(AEs),efficacy,and nursing intervention for sorafenibtherapy in patients with hepatocellular carcinoma(HCC).METHODS:We enrolled 37 consecutive patients withadvanced HCC who received sorafenib *** among baseline characteristics as well as AEoccurrence and tumor response,overall survival(OS),and treatment duration were *** nursingintervention program consisted of education regardingself-monitoring and AEs management,and telephoneRESULTS:A total of 37 patients were enrolled in the study,comprising 30 males(81%) with a median age of 71 *** disease control rate at 3 mo was 41%,and the median OS and treatment duration were 259 and 108 d,*** intervention was given to 24 patients(65%).Every patient exhibited some kinds of AEs,but no patients experienced G4 *** observed AEs > G2 included anorexia(57%),skin toxicity(57%),and fatigue(54%).Factors significantly associated with longer OS in multivariate analysis demonstrated that age ≤ 70 years,presence of > G2 skin toxicity,and absence of > G2 *** disease control rate in patients with > G2 skin toxicity was 13/20(65%),which was significantly higher compared with that in patients with no or G1 skin *** analysis revealed that nursing intervention and > G2 skin toxicity were independent significant predictors for longer treatment ***:Skin toxicity was associated with favorable outcomes with sorafenib therapy for advanced *** intervention contributed to better adher-ence,which may improve the efficacy of sorafenib.

关键词： Hepatocellular carcinoma Molecular targeted therapy Drug toxicity Surrogate marker Nursing intervention

An Advanced Oscillation Mixing Method for Improving the Cooling Uniformity in Quenching

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

材料热处理学报 2004年第5期25卷 475-479页

作者： Hiroyuki Hoshino Hiromitsu Murakami Hideo Yokota Satoshi Suda Hideki Tsuge koichi Terasaka Toshiaki Wakabayashi Nippon Oil Processing CO. LTD Niigata JapanOriental engineering CO. LTD Tokyo JapanNippon Oil Corp. Yokohama JapanNippon Oil Processing CO. LTD Niigata JapanKeio Univ. Yokohama Japan Keio Univ. Yokohama Japan Kagawa Univ. Takamatsu Japan

In quenching, the cooling uniformity is most important to diminish distortion occurring on work pieces. As a trial to accomplish uniform cooling, therefore, there exist various mixing methods of a quenchant and the quenchant circulation with an external pump has so far been the well accepted mixing method. However, this study proposes an advanced oscillation mixing method that can improve more the cooling uniformity in quenching. The proposed method includes a stirrer in oscillating motion, so that the simultaneous oscillating and mixing movements of the stirrer are considered to provide effectively the uniform cooling characteristics for the quenchant. In comparison with the case of the circulation pump mixing, the investigation using the oscillation mixing method has demonstrated the following two experimental facts: (1) the short vapor blanket stage caused by the quick breakage of the oil vapor blanket and (2) the reduced variation of the quenching distortion.

关键词：淬火剂冷却能力变形振动混合

Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2004年第5期10卷 733-736页

作者： Kaori Mochizuki Tatehiro kagawa Shinji Takashimizu Kazuya Kawazoe Sei-Ichiro Kojima Naruhiko Nagata Atsushi Nakano Yasuhiro Nishizaki koichi Shiraishi Masaru Itakura Norihito Watanabe Tetsuya Mine Shohei Matsuzaki Department of Internal Medicine Division of GastroenterologyTokai University School of MedicineBohseidaiIsehara 259-1193Japan

AIM:To test whether in vitro incubation of peripheral blood mononuclear cells (PBMC) with interferon (IFN) could efficiently decrease hepatitis C virus-RNA (HCV-RNA) amount and to analyze whether this effect was associated with clinical response to ***:Twenty-seven patients with histologically proven chronic hepatitis C were given intravenous administration of 6 million units (MU) IFN-β daily for 6 weeks followed by three times weekly for 20 weeks. PBMC collected before IFN therapy were incubated with IFN-β and HCV-RNA in PMBC was semi-quantitatively ***: Twenty-five patients completed IFN *** patients (32%) had sustained loss of serum HCV-RNA with normal serum ALT levels after IFN therapy (complete responders).HCV-RNA in PBMC was detected in all patients,whereas it was not detected in PBMC from healthy *** vitro administration of IFN-β decreased the amount of HCV-RNA in PMBC in 18 patients (72%). Eight of these patients obtained complete response. On the other hand,none of the patients whose HCV-RNA in PBMC did not decrease by IFN-β was complete responders. Multiple logistic regression analysis revealed that the decrease of HCV-RNA amount in PBMC by IFN-β was the only independent predictor for complete response (P<0.05).CONCLUSION:The effect of in vitro IFN-β on HCV in PBMC reflects clinical response and would be taken into account as a predictive marker of IFN therapy for chronic hepatitis C.

关键词：慢性丙型肝炎干扰素β 外周血单个核细胞免疫应答 HCV-RNA

新型淀粉样蛋白成像PET显像剂18F-FPYBF-2的生物分布和辐射剂量:首次在人体中的测定评估

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华核医学与分子影像杂志 2018年第9期38卷 646-647页

作者：李雪娜 Ryuichi Nishii Tatsuya Higashi Shinya kagawa Chio Okuyama Yoshihiko Kishibe Masaaki Takahashi Tomoko Okina Norio Suzuki Hiroshi Hasegawa Yasuhiro Nagahama koichi Ishizu Naoya Oishi Hiroyuki Kimura Hiroyuki Watanabe Masahiro Ono Hideo Saji Hiroshi Yamauchi 中国医科大学附属第一医院核医学科 Shiga Medical Center Research Institute Dept.of Molecular Imaging and Theranostics National Institute of Radiological Sciences (NIRS)National Institutes for Quantum and Radiological Science and Technology( QST)

目的近年来,苯并呋喃衍生物5-(5-(2-(2-(2-18F-氟乙氧基)乙氧基)乙氧基)苯并呋喃-2-基)-N-甲基吡啶-2-胺(18F-FPYBF-2)被证实是淀粉样蛋白成像的显像剂。已发现18F-FPYBF-2PET/CT是评估阿尔茨海默病（AD）有用且可靠的诊断工具（Higashi... 详细信息

目的近年来,苯并呋喃衍生物5-(5-(2-(2-(2-18F-氟乙氧基)乙氧基)乙氧基)苯并呋喃-2-基)-N-甲基吡啶-2-胺(18F-FPYBF-2)被证实是淀粉样蛋白成像的显像剂。已发现18F-FPYBF-2PET/CT是评估阿尔茨海默病（AD）有用且可靠的诊断工具（Higashi等,Ann Nucl Med,https://***/10.1007/s12149-018-1236-1,2018）。该研究首次在健康志愿者中评估诊断剂量18F-FPYBF-2的生物分布和辐射。方法 4名健康志愿者[男3名,女1名;平均年龄（40±17）岁,年龄范围25～56岁]行18FFPYBF-2 PET/CT显像,以评估辐射暴露和药代动力学。注射后0～10 min进行身体（胸部和腹部）的动态PET/CT显像,在注射18F-FPYBF-2后进行6次15 min的全身静态显像。重建PET和CT图像数据后,通过拟合动态显像和全身显像的感兴趣体积数据来估量个体器官时间-活度曲线。用OLINDA/EXM 2.0软件判定全身有效剂量（ED）。结果动态PET显像示肝胆系统和肾是18F-FPYBF-2清除的主要途径。肝脏、胆囊、胃和肾脏呈放射性高摄取,其次是肠和膀胱。成人剂量学模型估测的ED为（8.48±1.25）μSv/MBq。男性和女性中较高吸收剂量的器官为:肝脏[（28.98±12.49）和（36.21±15. 64）μGy/MBq],大脑[（20.93±4.56）和（23.05±5.03）μGy/MBq],成骨细胞[（9.67±1.67）和（10.29±1.70）μGy/MBq],小肠[（9.12±2.61）和（11.12±3.15）μGy/MBq]和肾脏[（7.81±2.62）和（8.71±2.90）μGy/MBq]。结论成人剂量学模型的ED与用于淀粉样蛋白PET显像的其他药物所致ED相似。18F-FPYBF-2作为评估AD的诊断工具,其诊断剂量185～370 MBq对患者而言是可耐受的。

关键词：阿尔茨海默病淀粉样蛋白显像健康志愿者正电子发射断层显像术生物分布辐射剂量测定 OLINDA/EXM

雷莫芦单抗用于经乐伐替尼治疗后进展的不可切除肝细胞癌的治疗效果

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Gastroenterology Report 2021年第2期9卷 133-138,I0002页

作者： Atsushi Hiraoka Takashi Kumada Toshifumi Tada Chikara Ogawa Joji Tani Shinya Fukunishi Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa koichi Takaguchi Kazuya Kariyama Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Kazuhito Kawata Hidenori Toyoda Hideko Ohama Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Korenobu Hayama Taeang Arai Michitaka Imai Yohei Koizumi Shinichiro Nakamura Kojiro Michitaka Yoichi Hiasa Masatoshi Kudo Gastroenterology Center Ehime Prefectural Central HospitalEhimeJapan Department of Gastroenterology and Hepatology Ogaki Municipal HospitalGifuJapan Department of Internal Medicine Himeji Red Cross HospitalHyogoJapan Department of Gastroenterology and Hepatology Takamatsu Red Cross HospitalTakamatsuJapan Department of Gastroenterology and Hepatology Kagawa universityKagawaJapan Department of Gastroenterology Osaka Medical CollegeOsakaJapan Division of Gastroenterology and Hepatology Department of Internal MedicineNippon Medical SchoolTokyoJapan Department of Gastroenterology and Metabology Ehime University Graduate School of MedicineEhimeJapan Center of Gastroenterology Teine Keijinkai HospitalSapporoJapan Department of Gastroenterology Saiseikai Niigata HospitalNiigataJapan Department of Hepatology Kagawa Prefectural Central HospitalTakamatsuJapan Department of Gastroenterology Okayama City HospitalOkayamaJapan Department of Gastroenterology Asahi General HospitalAsahiJapan Department of Gastroenterology Toyama University HospitalToyamaJapan Division of Gastroenterology and Hepatology Otakanomori HospitalKashiwaJapan Department of Gastroenterology Tokushima Prefectural Central HospitalTokushimaJapan Hepato-biliary Center Matsuyama Red Cross HospitalMatsuyamaJapan Department of Hepatology Hamamatsu University School of MedicineHamamatsuJapan Department of Gastroenterology Kindai UniversityOsakaJapan

背景:在日本,乐伐替尼可用于不可切除原发性肝癌的一线、二线或三线治疗。本研究评估新近研发的雷莫芦单抗用于经乐伐替尼治疗后进展的不可切除的原发性肝癌的疗效。方法:2018年5月至2020年1月间在日本16家中心接受乐伐替尼治疗的385例... 详细信息

背景:在日本,乐伐替尼可用于不可切除原发性肝癌的一线、二线或三线治疗。本研究评估新近研发的雷莫芦单抗用于经乐伐替尼治疗后进展的不可切除的原发性肝癌的疗效。方法:2018年5月至2020年1月间在日本16家中心接受乐伐替尼治疗的385例不可切除原发性肝癌患者中,我们将其中接受雷莫芦单抗作为下一线治疗的28例患者纳入研究,对其治疗效果进行回顾性分析。结果:28例患者中位年龄70岁,中位白蛋白-胆红素(ALBI)评分为2.19。28例患者中,23例为男性;21例为Child-Pugh A级,7例为Child-Pugh B级;3例为BCLC B期,25例为BCLC C期。雷莫芦单抗用于二线、三线和四线治疗的病例分别为14例、9例和5例患者。26例患者获得疗效评估,客观缓解率为3.8%(1/26),疾病控制率为42.3%(11/26);中位疾病进展时间为2个月。未继续接受雷莫芦单抗治疗的原因包括16例出现疾病进展和2例出现3级不良反应(消化道出血和腹水)。结论:我们的初步研究显示,对于乐伐替尼治疗进展的不可切除原发性肝癌,雷莫芦单抗并没有获得预期的治疗效果。

关键词： hepatocellular carcinoma ramucirumab lenvatinib sorafenib